B cells have important pathogenic roles in systemic lupus erythematosus (SLE): they produce autoantibodies, secrete inflammatory cytokines and might promote expansion of autoreactive T cells via ...

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

and indicates a mechanism for this gene's influence via its effect in B cells. The identification of this molecular mechanism could lead to further understanding of the role of IRF5 in SLE.

Artiva Biotherapeutics' CEO Fred Aslan, MD, discusses the concept of an immune reset and what the company is tracking in ...

T- and B-cell metabolic changes in the progression of autoimmune diseases, taking Systemic Lupus Erythematosus (SLE) as an ...

Interestingly, Sana’s dual target CD19/CD47 enable them to eliminate B cells causing SLE, while CD47 deletion reduces inflammation and reduces the autoimmune inflammation associated with SLE and ...

Patient enrollment in SLE, systemic sclerosis (SSc), idiopathic ... In the Phase 1 GLEAN trial, ADI-001 was shown to target B-cells via an anti-CD20 CAR and demonstrated robust exposure and ...

Described today in the journal Science Translational Medicine, the finding gives oncologists a new target for developing immunotherapies: double negative memory B cells, so-called because they are ...